Iveric bio, Still A 5+% Opportunity
Iveric bio, Inc., focused on developing treatments for retinal diseases, has announced its acquisition by Astellas Pharma Inc.Iveric bio, Inc. stock trades at a discount of over 5% for an
Chandra